FSC Wealth Advisors LLC Buys Shares of 1,132 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

FSC Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 1,132 shares of the biopharmaceutical company’s stock, valued at approximately $65,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Handelsbanken Fonder AB raised its holdings in Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares during the last quarter. TD Asset Management Inc increased its position in shares of Halozyme Therapeutics by 28.1% in the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares in the last quarter. Boston Trust Walden Corp acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $23,211,000. Swedbank AB purchased a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $13,927,000. Finally, Epoch Investment Partners Inc. boosted its position in shares of Halozyme Therapeutics by 23.3% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after buying an additional 270,579 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO stock opened at $51.55 on Wednesday. The stock has a market capitalization of $6.56 billion, a price-to-earnings ratio of 21.30, a price-to-earnings-growth ratio of 0.49 and a beta of 1.27. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. Halozyme Therapeutics, Inc. has a 52-week low of $32.83 and a 52-week high of $65.53. The stock’s fifty day simple moving average is $58.52 and its 200-day simple moving average is $51.46.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. During the same period last year, the company earned $0.68 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $9,254,244.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,881 shares of company stock valued at $5,169,834. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. The Goldman Sachs Group lifted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Morgan Stanley upped their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. TD Cowen raised their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, October 4th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.44.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.